Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations

Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy and are now the preferred treatment for several tumor types. Though ICIs have shown remarkable efficacy in several cancer histologies, in many cases providing long-term disease control, not all patients will derive clinical benef...

Descripción completa

Detalles Bibliográficos
Autor principal: Principe, Daniel R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263148/
https://www.ncbi.nlm.nih.gov/pubmed/35798829
http://dx.doi.org/10.1038/s41598-022-15714-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263148/
https://www.ncbi.nlm.nih.gov/pubmed/35798829
http://dx.doi.org/10.1038/s41598-022-15714-5

Ejemplares similares